Renovo's Juvidex fails to accelerate healing of skin-graft wounds in Phase II
This article was originally published in Scrip
Executive Summary
Renovo's anti-scarring product Juvidex (mannose-6-phosphate) has failed to meet the primary endpoint of a placebo-controlled Phase II trial testing its ability to accelerate healing of skin-graft donor sites.